| 产品详情 |
| Edit |   |
|---|
| Product Name | Human Apolipoprotein CII ELISA Kit |
|---|
| Description | This assay employs the quantitative sandwich enzyme immunoassay technique. An antibody specific for ApoCII has been pre-coated onto a microtiter plate. Standards or samples are pipetted into the wells and any ApoCII present is bound by the immobilized antibody. After washing away any unbound substances, a biotin-conjugated antibody specific for ApoCII is added to each well and incubate. Following a washing to remove unbound substances, streptavidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After washing away any unbound antibodyenzyme reagent, a substrate solution (TMB) is added to the wells and color develops in proportion to the amount of ApoCII bound in the initial step. The color development is stopped by the addition of acid and the intensity of the color is measured at a wavelength of 450nm ±2nm. The concentration of ApoCII in the sample is then determined by comparing the O.D of samples to the standard curve. Sample Types: plasma, serum or other biological fluids. Range: 1.56 - 100 ng/ml. Sensitivity: 1 ng/ml. Time: 4.5 hours • Apolipoprotein CII (ApoCII) is a member of the apolipoprotein C1 family. ApoCII is expressed primarily in the liver, and it is activated when monocytes differentiate into macrophages. A pseudogene of this gene is located 4 kb downstream in the same orientation, on the same chromosome. This gene is mapped to chromosome 19, where it resides within an apolipoprotein gene cluster. Alternatively spliced transcript variants have been found for this gene, but the biological validity of some variants has not been determined. [provided by RefSeq, Jul 2008] Apolipoprotein CII (ApoCII) is an inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with betamigrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein. |
|---|
| Size | 1 x 96 well |
|---|
| Concentration | n/a |
|---|
| Applications | RUO |
|---|
| Other Names | Apolipoprotein CII, APO CII |
|---|
| Gene, Accession, CAS # | n/a |
|---|
| Catalog # | ARG81209 |
|---|
| Price | |
|---|
| Order / More Info | Human Apolipoprotein CII ELISA Kit from EAGLE BIOSCIENCES INC. |
|---|
| Product Specific References | n/a |
|---|
| 产品资料 |
|
|